.png)
Key takeaways:
• Insurance reviewers rely on the clinical information submitted to assess medical necessity; missing details can limit that review.
• Clinical notes should explain the patient’s findings, why exome or genome sequencing is appropriate, any prior diagnostic evaluation, potential impact on care, and counseling provided.
• Relevant ICD-10 codes and supplemental documentation can support a patient-specific clinical narrative.
• A complete clinical history also provides important context for genomic interpretation.
Five questions every clinical note should answer to support genetic testing coverage
Clinicians know why their patients need genetic testing, but that rationale is not always fully reflected in the information available to insurance reviewers. For exome or genome sequencing, a clear clinical note explains why a genetic condition is suspected, why comprehensive sequencing is appropriate, what diagnostic evaluation has occurred, when applicable, and how results could inform care. A strong note does not have to be lengthy—it needs to answer five practical questions about the individual patient.
1. Why this patient?
Describe the clinical findings and relevant family history that support a suspected genetic condition.
Include relevant symptoms, developmental concerns, neurological findings, congenital anomalies, family history, or other clinical features that suggest a possible genetic cause.
Connect the patient’s specific findings to the suspected genetic etiology rather than relying on a general statement of concern.
2. Why exome or genome?
Explain why comprehensive sequencing is an appropriate diagnostic approach for this patient.
This may include:
- A complex or nonspecific clinical presentation
- Multiple unexplained findings that may not be attributable to a single condition
- The need for a broad diagnostic approach
- Professional society recommendations supporting exome or genome sequencing
Make the connection between the patient’s findings and the selected test explicit.
3. What diagnostic evaluation has been performed, if any?
Describe the diagnostic evaluation completed to date.
This may include previous genetic testing, laboratory studies, imaging findings, or specialist evaluations.
If previous genetic testing was negative or inconclusive, document those results. If exome or genome sequencing is being pursued early in the diagnostic process, explain why it is an appropriate first-line or early diagnostic approach for this patient. Prior genetic testing is not always required before exome or genome sequencing; clinical recommendations and insurer coverage criteria may differ.
4. How might results impact this patient’s care?
Be specific about how the results could inform future medical management for this individual patient.
Potential examples include:
- Treatment decisions
- Medication selection or avoidance
- Surveillance or monitoring
- Referrals to specialists
- Procedures or surgical planning
- Prognosis
- Family testing and recurrence-risk counseling
Avoid relying solely on general statements that genetic testing may affect management. Instead, connect potential results to decisions relevant to this patient. For example, for a child with unexplained developmental delay and seizures, identifying an underlying genetic diagnosis could inform antiseizure medication selection, targeted surveillance, or specialist referrals. Document potential impacts that are clinically reasonable for the individual patient.
5. Has genetic counseling been provided and documented?
Many health plans request documentation of genetic counseling, but requirements vary. Document counseling provided to the patient or family by the ordering clinician or another qualified healthcare professional, as appropriate, including:
- The purpose of testing
- What the results may reveal
- The implications for the patient and family
- Follow-up plans
If the patient was evaluated by a genetic counselor or genetics specialist, include that information and the relevant consultation note.
Where should medical necessity be documented?
Whenever possible, document the rationale for testing directly in the patient’s clinical note, assessment and plan, or visit summary. The clinical note should serve as the foundation of the medical-necessity documentation by explaining why a genetic condition is suspected, why exome or genome sequencing is appropriate, and how the results could inform this patient’s care.
If the clinical note does not fully capture the patient’s clinical story, additional documentation, such as a Letter of Medical Necessity (LMN), may help provide the information a health plan needs to evaluate the request.
Include all relevant ICD-10 codes
Clinical notes and diagnosis codes work together to support insurance review. ICD-10 codes help communicate the patient’s documented clinical picture but do not replace a clear narrative rationale for sequencing.
Include all clinically relevant, documented ICD-10 codes that accurately reflect the patient’s diagnoses, signs, symptoms, and findings, not just the primary indication for testing.
Rare disease patients can have complex patterns of symptoms and findings. A diagnosis or clinical feature that may seem unrelated could be an important part of the overall clinical picture. Including all relevant ICD-10 codes helps give the health plan a more complete view of the patient and the medical necessity for testing.
Accurate diagnosis coding and a patient-specific clinical note together provide a more complete basis for medical necessity review.
A complete clinical history also supports interpretation
The value of a complete clinical picture extends beyond insurance review. The clinical information submitted with an order also provides GeneDx experts with important context for genomic interpretation.
Detailed information about the patient’s symptoms, clinical findings, family history, and prior testing can help our experts understand the patient’s phenotype and evaluate genetic findings in the context of their individual clinical presentation.
Supporting medical necessity with clear clinical documentation
Strong clinical documentation helps insurance companies understand why exome or genome sequencing is medically necessary for your patient. By clearly communicating the patient’s clinical findings, rationale for testing, and potential impact on care, you can help support insurance coverage while also providing valuable information for genomic interpretation.
You know your patient best. GeneDx is here to help you navigate insurance requirements and the prior authorization process. Together, we can help reduce unnecessary barriers and move patients and families closer to the answers they need.
